News

Yahoo Finance4y
Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment
NORTH HAVEN, Conn. and NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Insignis Therapeutics (“Insignis”), a biotech company focused on developing innovative therapeutics for anaphylaxis ...